S-1/A: Splash Beverage Group Files for Resale of Shares

Splash Beverage Group, Inc. (SBEV) has filed an S-1/A amendment to register the resale of up to 5,000,000 shares of common stock by C/M Capital Master Fund, LP, detailing a strategic shift towards the cannabinoid and wellness sectors.

Summary

• Splash Beverage Group, Inc. (SBEV) has filed an S-1/A amendment to register the resale of up to 5,000,000 shares of common stock by C/M Capital Master Fund, LP.
• The company is transitioning from its legacy beverage business to focus on the cannabinoid and wellness economy.
• This transition includes acquiring exclusive worldwide rights to CannEpil, a pharmaceutical product for epilepsy and neurological conditions.
• The company has undergone a one-for-four reverse stock split effective July 24, 2026.
• Splash Beverage Group is facing significant financial challenges, including recurring losses and a going concern warning from its auditors.
• The company is also working to regain compliance with NYSE American continued listing standards, with a plan submitted to the NYSE.
• The filing details a strategic investment in Avicanna Inc. and a collaboration agreement for CannEpil's veterinary development.
• The company plans to use proceeds from the equity line of credit for working capital, to resolve disputes, and for general corporate purposes.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's ongoing going concern issues, significant operating losses, and the dilutive nature of its financing arrangements, despite the strategic pivot to the cannabinoid market.

Positives

• Strategic pivot towards the growing cannabinoid and wellness market with the acquisition of CannEpil.
• Secured an equity line of credit (ELOC) with C/M Capital Master Fund, LP, providing potential access to capital.
• Entered into a development and collaboration agreement for CannEpil's veterinary applications.
• Appointed experienced leadership in the cannabinoid sector (Brady Cobb and Michael Bondurant).
• Received acceptance from NYSE American for its compliance plan, providing a cure period until January 29, 2027.

Negatives

• Auditors have issued a going concern warning due to recurring losses and negative working capital.
• Significant operating losses reported, with a net loss of $25.2 million for the year ended December 31, 2025.
• The company has failed to meet NYSE American's stockholders' equity requirement multiple times.
• The stock price has been volatile and has traded below $0.10 per share, leading to a trading halt.
• Potential for substantial dilution to existing stockholders due to the ELOC and other convertible securities.
• The company has no sales and marketing employees and estimates needing at least $2 million for development and operations.
• Significant legal proceedings and disputed claims, including a $1.7 million claim from TapouT, LLC.
• Material weaknesses in internal control over financial reporting due to limited resources and staff.

Risks

• Inability to raise sufficient capital to fund operations, development, and strategic transactions.
• Failure to regain compliance with NYSE American continued listing standards, leading to delisting.
• The CannEpil product may not achieve market acceptance or regulatory approval in the U.S.
• Potential for significant dilution from the issuance of common stock under the ELOC and other convertible securities.
• Dependence on the Licensor for manufacturing and potential intellectual property protection challenges.
• Competition from established players in the cannabinoid and wellness industry.
• Uncertainty regarding the success of strategic transactions and integration of acquired businesses.
• The company's limited cash resources and lack of dedicated sales and marketing personnel.

Future Outlook

The company aims to transition to the regulated wellness and cannabinoid markets, focusing on the development and commercialization of CannEpil for both human and veterinary use. However, its future success is heavily dependent on its ability to secure additional financing, regain compliance with NYSE listing standards, and successfully navigate the complex regulatory landscape for cannabinoid products.

Management Comments

• Management believes its public platform, industry relationships, and leadership experience present opportunities to participate in higher-growth segments of the cannabinoid health and wellness industry.
• Management believes its experience provides a differentiated perspective as it evaluates opportunities across pharmaceutical, wellness, and consumer cannabinoid markets.
• Management is focused on pursuing capital-efficient opportunities that leverage strategic partnerships, proprietary intellectual property, and experienced leadership while seeking to create sustainable long-term value for shareholders.

Industry Context

StockSavvy.ai notes that Splash Beverage Group's pivot to the cannabinoid and wellness sector aligns with a broader industry trend of companies seeking growth in these burgeoning markets. The company's focus on a pharmaceutical-grade cannabinoid product like CannEpil positions it within a segment that, if successful, could offer significant long-term value, but also faces substantial regulatory hurdles and competition.

Comparison to Industry Standards

• The company's financial situation, including recurring losses and a going concern warning, is a significant deviation from industry standards for established, profitable companies.
• The reliance on an equity line of credit (ELOC) for funding is a common strategy for early-stage or financially distressed companies, but it often leads to significant dilution, which is a concern compared to companies with more stable, traditional financing.
• The company's efforts to regain compliance with NYSE listing standards highlight the challenges faced by smaller companies in meeting the financial and governance requirements of major exchanges, unlike larger, more established players.

Legal Proceedings

• TapouT, LLC filed a complaint for breach of contract seeking approximately $1,700,000.
• The company is resolving alleged and potential claims from investors referred to as Uptime Investor Claims.
• A former employee, Miguel Ramirez, filed a claim for back wages and penalties.
• A demand for payment was received from Decathlon Alpha IV, L.P. regarding a Revenue and Loan Security Agreement.
• A complaint was filed by Premium Merchant Funding 26, LLC alleging breach of contract, with a default judgment entered.
• A demand for payment was made by representatives for Jeremy Reichman, Albert Reichman, Seth Yanofsky, and Daniel Braun.
• Demands for payment were received from Learfield Communications, LLC and Mainfreight, Inc.
• A demand for payment was received from Cobalt Funding Solutions.

Related Party Transactions

• Sublease of office space from Northswell Consulting, LLC, an entity owned by Brady Cobb, for $4,750 per month.
• Consulting agreement with former President William Meissner for $5,000 per month, plus stock options.
• Consulting agreement with former director Robert Nistico for $5,000 per month, plus stock options and expense reimbursement.
• Outstanding related party advances from former CEO Robert Nistico.

Stakeholder Impact

• Existing shareholders face significant dilution risk from the ELOC and other convertible securities.
• The company's financial instability and potential delisting from NYSE American could negatively impact shareholder value.
• Employees may face uncertainty due to the company's financial situation and ongoing strategic transformation.
• Creditors and suppliers may face risks related to the company's ability to meet its financial obligations.

Next Steps

• Secure additional financing to fund operations and development of CannEpil.
• Regain compliance with NYSE American continued listing standards by January 29, 2027.
• Advance the development and commercialization of CannEpil for human and veterinary use.
• Explore and potentially complete strategic transactions.
• Obtain necessary regulatory approvals for CannEpil in the U.S.

Key Dates

Recommendation

The company is in a precarious financial position, marked by recurring losses, a going concern warning, and a history of failing to meet exchange listing requirements. While the strategic pivot to the cannabinoid market is a positive step, the significant dilution from its financing arrangements (ELOC) and the substantial capital required to execute its plans, coupled with ongoing legal and regulatory challenges, present a high-risk investment profile. The lack of current revenue and operational staff further exacerbates these concerns, making it difficult to foresee a near-term turnaround that would justify a buy or hold recommendation.

Keywords

Cannabinoid, Wellness, CannEpil, Epilepsy Treatment, Pharmaceutical, Veterinary Medicine, Equity Line of Credit, SEC Filing